The europe antidepressants drugs, devices and therapies market region is seeing an escalated growth of 1.77% CAGR during the forecasting years of 2019-2027. Europe has strict monitoring and certification procedures to ensure full safety and traceability of medical devices.

EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET FORECAST 2019-2027

Europe Antidepressants Drugs, Devices and Therapies Market by Antidepressants Drugs (Serotonin and Norepinephrine Reuptake Inhibitors (Snris), Tricyclic Antidepressants (Tca), Monoamine Oxidase Inhibitors (Maois), Atypical Antidepressants, Selective Serotonin Reuptake Inhibitors, Benzodiazepines, Anticonvulsants, Beta-blockers, Other Antidepressants Drugs) by Devices (Deep Brain Stimulators, Fisher Wallace Stimulators, Transcranial Magnetic Stimulator, Other Devices) by Therapies (Cognitive Behavior Therapy (Cbt), Electroconvulsive Therapy (Ect), Rational Emotive Behavior Therapy (Rebt), Other Therapies) by Geography.

Request free sample

Report Summary

Recent research points to myriad reasons, many overlapping as the risk factors for depression, in particular less developed countries often lack the infrastructure to collect data on depression, and also are less likely to recognise it as an illness, where the people in these countries are more likely to feel a social stigma against asking for professional help. Countries like Germany, the United Kingdom, France, Spain, Italy, Russia and the remaining countries forming the Rest of Europe where depression poses a serious concern, and further adds burden on to the health. The region is seeing an escalated growth of 1.77% CAGR in the antidepressants drugs, devices and therapies market during the forecasting years of 2019-2027.

Europe has strict monitoring and certification procedures to ensure full safety and traceability of medical devices. The governments are cautious over the medical devices and proposed legislation seeking to increase patient safety. Moreover, the country with the fastest growth rate and has grasped the largest market share by revenue in Germany, where depression is one of the most commonly occurring disorders. According to several studies, Germany has a prevalence rate of approximately 4.5-5% for depression, and mental disorders are a leading cause for early retirement in the country. So, to alleviate these issues, the government has stipulated several incentives for subsidizing mental healthcare costs that are expected to be beneficial for the market expansion in the country.

The companies operating in the region are Eli Lilly and Company, Abbot Laboratories, Allergan PLC, Pfizer, Neuronetics, Mayo Clinic, H. Lundbeck AS, Brainsway, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd. and GlaxoSmithKline.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IS THE DOMINANT DRUG IN ANTIDEPRESSANTS MARKET
        • DEEP BRAIN STIMULATOR IS EXPECTED TO GROW FAST AMONG OTHER DEVICES OVER THE FORECAST PERIOD
        • COGNITIVE BEHAVIOR THERAPY (CBT) IS THE LARGEST CONTRIBUTOR TO THE ANTIDEPRESSANTS THERAPIES MARKET
    1. MARKET DYNAMICS
      • MARKET DEFINITION & SCOPE
      • MARKET DRIVERS
        • RISE IN THE NUMBER OF DEPRESSION PATIENTS
        • INCREASE IN AGING POPULATION
        • RISING CONSCIOUSNESS OF DEPRESSION AS A MEDICAL DISORDER
        • SURGE IN SALES OF ANTIDEPRESSANTS
      • MARKET RESTRAINTS
        • HIGH COST OF DEPRESSION THERAPY
        • PATENT EXPIRATION FACED BY THE COMPANIES
        • DELAY IN PRODUCT LAUNCHES
      • MARKET OPPORTUNITIES
        • HUGE MARKET POTENTIAL
        • MORE PREFERENCE FOR PERSONNEL THERAPY & DEVICE TREATMENT
      • MARKET CHALLENGES
        • STIFF COMPETITION FROM THE GENERIC DRUGMAKERS
    1. MARKET BY ANTIDEPRESSANTS DRUGS
      • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
      • TRICYCLIC ANTIDEPRESSANTS (TCA)
      • MONOAMINE OXIDASE INHIBITORS (MAOIs)
      • ATYPICAL ANTIDEPRESSANTS
      • SELECTIVE SEROTONIN REUPTAKE INHIBITORS
      • BENZODIAZEPINES
      • ANTICONVULSANTS
      • BETA-BLOCKERS
      • OTHER ANTIDEPRESSANTS DRUGS
    2. MARKET BY DEVICES
      • DEEP BRAIN STIMULATORS
      • FISHER WALLACE STIMULATORS
      • TRANSCRANIAL MAGNETIC STIMULATOR
      • OTHER DEVICES
    3. MARKET BY THERAPIES
      • COGNITIVE BEHAVIOR THERAPY (CBT)
      • ELECTROCONVULSIVE THERAPY (ECT)
      • RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
      • OTHER THERAPIES
    4. KEY ANALYTICS
      • PORTER’S FIVE FORCE MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • VALUE CHAIN ANALYSIS
        • FOR DRUGS
        • FOR DEVICES
      • KEY BUYING CRITERIA
    5. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • GERMANY
        • UNITED KINGDOM
        • FRANCE
        • SPAIN
        • ITALY
        • RUSSIA
        • ROE (REST OF EUROPE)
    1. COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
      • COMPANY PROFILE
        • ABBOT LABORATORIES
        • ALLERGAN PLC
        • BOEHRINGER INGELHEIM GMBH
        • BRAINSWAY
        • ELI LILLY AND COMPANY
        • HOFFMANN-LA ROCHE LTD.
        • GLAXOSMITHKLINE
        • LUNDBECK AS
        • MAYO CLINIC
        • NEURONETICS
        • PFIZER

    TABLE LIST

    TABLE 1 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)

    TABLE 2 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ANTIDEPRESSANTS DRUGS, 2019-2027, (IN $ MILLION)

    TABLE 3 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY DEVICES, 2019-2027, (IN $ MILLION)

    TABLE 4 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY THERAPIES, 2019-2027, (IN $ MILLION)

    TABLE 5 OPPORTUNITY MATRIX

    TABLE 6 VENDOR LANDSCAPE

    TABLE 7 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

    FIGURE LIST 

    FIGURE 1 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET SHARE, BY DRUGS 2018 & 2027 (%)

    FIGURE 2 SNRIs MARKET, 2019 – 2027 (IN $ MILLION)

    FIGURE 3 DEEP BRAIN STIMULATORS MARKET, 2019 – 2027 (IN $ MILLION)

    FIGURE 4 COGNITIVE BEHAVIOR THERAPY (CBT) MARKET ($ MILLION)

    FIGURE 5 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COGNITIVE BEHAVIOR THERAPY (CBT), 2019-2027, (IN $ MILLION)

    FIGURE 6 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ELECTROCONVULSIVE THERAPY (ECT), 2019-2027, (IN $ MILLION)

    FIGURE 7 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT), 2019-2027, (IN $ MILLION)

    FIGURE 8 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, OTHER THERAPIES, 2019-2027, (IN $ MILLION)

    FIGURE 9 PORTER’S FIVE FORCE MODEL

    FIGURE 10 VALUE CHAIN OF ANTIDEPRESSANT DRUGS

    FIGURE 11 VALUE CHAIN ANALYSIS FOR DEVICE MARKET

    FIGURE 12 EUROPE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, REGIONAL OUTLOOK, 2018 & 2027, (%)

    FIGURE 13 GERMANY ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 14 UNITED KINGDOM ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 15 FRANCE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 16 SPAIN ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 17 ITALY ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 18 RUSSIA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 19 ROE ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 20 MARKET SHARE OF ANTIDEPRESSANTS DRUG MANUFACTURERS (PERCENTAGE OF SALES), 2018

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • GERMANY
        • UNITED KINGDOM
        • FRANCE
        • SPAIN
        • ITALY
        • RUSSIA
        • ROE (REST OF EUROPE)
    1. MARKET BY ANTIDEPRESSANTS DRUGS
      • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
      • TRICYCLIC ANTIDEPRESSANTS (TCA)
      • MONOAMINE OXIDASE INHIBITORS (MAOIs)
      • ATYPICAL ANTIDEPRESSANTS
      • SELECTIVE SEROTONIN REUPTAKE INHIBITORS
      • BENZODIAZEPINES
      • ANTICONVULSANTS
      • BETA-BLOCKERS
      • OTHER ANTIDEPRESSANTS DRUGS
    2. MARKET BY DEVICES
      • DEEP BRAIN STIMULATORS
      • FISHER WALLACE STIMULATORS
      • TRANSCRANIAL MAGNETIC STIMULATOR
      • OTHER DEVICES
    3. MARKET BY THERAPIES
      • COGNITIVE BEHAVIOR THERAPY (CBT)
      • ELECTROCONVULSIVE THERAPY (ECT)
      • RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
      • OTHER THERAPIES

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS